Tetanus immunoglobulin

Generic name
Tetanus immunoglobulin
Brand name
ATC Code
J06BB02
Compare …

Tetanus immunoglobulin

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Prophylaxis for injuries: Immuno-incompetent people, irrespective of the vaccination status against tetanus
  • Intramuscular
    • 0 years up to 18 years
      [3]
      • 250 IU/dose, once only. in combination with 1 dosis of tetanus toxoid (DTP, young children DPTP) in fully vaccinated patients. If not or incompletely vaccinated, catch up on the missing vaccinations. .

      • Post-exposure prophylaxis with tetanus immunoglobulin would seem to be useful up to 3 weeks after the wound.
Clinically manifest tetanus
  • Intramuscular
    • 1 month up to 18 years
      • 3.000 IU/day in 1 dose
      • Duration of treatment:

        2 days

      • Directions for administration:

        Inject slowly, deep into the muscle. The preparation should preferably be brought to body temperature before administering it.

      • Active immunization after recovery.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

IMMUNOGLOBULINS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Immunoglobulins, normal human
J06BA02
J06BA01
Specific immunoglobulins
J06BB01
J06BB04
J06BB03
Antibacterial monoclonal antibodies
J06BC03
IMMUNOGLOBULINS, NORMAL HUMAN
J06BA02
J06BA01
Antiviral monoclonal antibodies
J06BD07
J06BD08
J06BD01

References

  1. Rademaker C.M.A. et al, Geneesmiddelen Formularium voor Kinderen, 2009
  2. Gezondheidsraad, Immunisatie tegen tetanus bij verwonding, Den Haag, 2003
  3. LCI, Richtlijn Tetanus, www.lci.rivm.nl, Vaststelling LCI 29 januar 2019, update PEP kinderen 5 aug 2020

Changes

Therapeutic Drug Monitoring


Overdose